Adagene (ADAG) News
NASDAQ: ADAGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.76-0.25 (-12.44%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ADAG news summary
We found 6 recent headlines mentioning Adagene (ADAG): 4 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. ADAG is making an outsized move today, down 12.44% at $1.76, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Adagene Inc. Announces First Patient Dosed in Phase 1 Study of ADG138", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Adagene headlines
- Adagene Inc. Announces First Patient Dosed in Phase 1 Study of ADG138Adagene Inc. announced that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format and…Nasdaq
- Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%(RTTNews) - Shares of several biotech and healthcare companies moved higher amid clinical updates, quarterly results and increased trading activity. Akanda and Adagene rallied without fresh…NasdaqADAG, AKAN, ANTX, CUE
- Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerAdagene Inc. and City of Hope have announced the launch of an investigator-initiated Phase 1 clinical trial to explore a new combination therapy for patients with advanced microsatellite stable…Nasdaq
- Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerStudy designed by medical oncologist to accelerate lifesaving care to patientsGlobeNewswire
- Adagene Inc. Announces Completion of Phase 2 Enrollment of Muzastotug and Expected US$8.0 million Second Closing of Sanofi InvestmentAdagene Inc. announced completion of enrollment in its randomized Phase 2 dose-optimization trial of muzastotug in combination with KEYTRUDA in patients with late-line microsatellite stable…Nasdaq
- Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceSAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…GlobeNewswire